FDA Commissioner Margaret Hamburg talks about new regulatory tools, surrogate endpoints, ebola, and more on Engaging Innovation.
Friends of Cancer Research and the Engelberg Center for Health Care Reform at Brookings co-hosted discussions on critical issues in cancer care.
Friends of Cancer Research is our country's leading voice in advocating for policies and solutions that will get treatments to patients in the safest and quickest way posible.
Researchers, drug developers, and patient advocates share their thoughts about Lung-MAP
Eleven novel drugs have already been approved through the FDA's Breakthrough Therapy program.
Friends of Cancer Research's 2013 Annual Report is now available for download.
Patients, drug developers, and regulators discussed Breakthrough Therapy's progress at our May briefing
Ranibizumab (Lucentis) - (Genentech)
for the treatment of diabetic retinopathy
Ixazomib - (Takeda Therapeutics)
for the treatment of relapsed or refractory systemic light-chain (AL) amyloidosis
JCAR015 - (Juno Therapeutics)
for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia
FDA Commissioner Dr. Margaret Hamburg commented on pressing issues in drug development and regulation.
"There isn't a day where I'm not overwhelmed by how many people are dealing with this disease, and that's what drives all of our work at Friends of Cancer Research."
FRIENDS OF CANCER RESEARCH1800 M Street NW Suite 1050 | Washington, DC 20036202.944.6700